Persistent attenuation of nicotine self-administration in rats by co-administration of chronic nicotine infusion with the dopamine D1 receptor antagonist SCH-23390 or the serotonin 5-HT2C agonist lorcaserin
| Autor: | Blair K.A. Willette, Brandon J. Hall, Corinne Wells, Amir H. Rezvani, Susan Slade, Devon DiPalma, Edward D. Levin |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Agonist
Nicotine medicine.drug_class media_common.quotation_subject Clinical Biochemistry Self Administration Pharmacology Toxicology Biochemistry Article Lorcaserin Rats Sprague-Dawley 03 medical and health sciences Behavioral Neuroscience 0302 clinical medicine Dopamine receptor D1 Dopamine Animals Medicine Biological Psychiatry media_common Behavior Animal business.industry Receptors Dopamine D1 Addiction Infusion Pumps Implantable Tobacco Use Disorder Benzazepines Nicotine replacement therapy Tobacco Use Cessation Devices Rats 030227 psychiatry Nicotinic agonist Drug Therapy Combination Female Smoking Cessation business Serotonin 5-HT2 Receptor Agonists 030217 neurology & neurosurgery medicine.drug |
| Zdroj: | Pharmacology Biochemistry and Behavior. 176:16-22 |
| ISSN: | 0091-3057 |
| DOI: | 10.1016/j.pbb.2018.11.002 |
| Popis: | Tobacco addiction each year causes millions of deaths worldwide. Brain nicotinic acetylcholine receptors have been shown to be central to tobacco addiction. Nicotine replacement therapy aids tobacco cessation, but the success rate is still far too low. This may in part be due to the fact that neurons with nicotinic receptors are not the only neural systems involved in tobacco addiction. Interacting neural systems also play important roles in tobacco addiction. Nicotine increases the release of a variety of neurotransmitters, including dopamine and serotonin. Dopamine, in particular dopamine D(1) receptors, have been shown to be involved in the reinforcing action of nicotine. Serotonin through its actions on 5-HT(2C) receptors has been shown to play a key role in modulating the reinforcement of addictive drugs, including nicotine and alcohol. Combination of treatments could provide greater treatment efficacy. These studies were conducted to evaluate combination therapies utilizing nicotine replacement therapy in conjunction with either a dopamine D(1) receptor antagonist SCH-23390 or a serotonin 5-HT(2C) receptor agonist, lorcaserin. Female Sprague-Dawley rats were given access to self-administer nicotine via IV infusions. Osmotic pumps were implanted to reproduce the kinetic of chronic nicotine patch therapy. SCH-23390 (0.02 mg/kg) or lorcaserin (0.6 mg/kg) were administered prior to nicotine self-administration sessions. Reproducing earlier findings SCH-23390, lorcaserin and nicotine replacement therapy were effective at reducing IV nicotine self-administration. 5HT(2C) agonist treatment had additive effects with chronic nicotine infusion for significantly lowering nicotine self-administration. This study demonstrates the feasibility of combination of chronic nicotine with therapies targeting non-nicotinic receptors as treatment options for tobacco addiction. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect